Evidence map›Paper›PMID 26834553›Full record

ArticleFrontiers in molecular neuroscience2015

Missense Mutation R338W in ARHGEF9 in a Family with X-linked Intellectual Disability with Variable Macrocephaly and Macro-Orchidism.

Philip Long, Melanie M May, Victoria M James, Simone Grannò, John P Johnson, Patrick Tarpey, Roger E Stevenson, Kirsten Harvey, Charles E Schwartz, Robert J Harvey

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. A novelThe Journal of international medical research · 2021
    Article
  3. Article
  4. Article
  5. Review
  6. Targeting GABAFrontiers in molecular neuroscience · 2019
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Neurology. Genetics · 2017
    Article
  13. Neurology. Genetics · 2017
    Article
  14. Article
  15. The α3 subunit of GABAThe Journal of biological chemistry
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Philip LongDepartment of Pharmacology, UCL School of Pharmacy London, UK.
Melanie M MayJC Self Research Institute, Greenwood Genetic Center Greenwood, SC, USA.
Victoria M JamesDepartment of Pharmacology, UCL School of Pharmacy London, UK.
Simone GrannòDepartment of Pharmacology, UCL School of Pharmacy London, UK.
John P JohnsonDepartment of Medical Genetics, Shodair Children's Hospital Helena, MT, USA.
Patrick TarpeyWellcome Trust Sanger Institute, Wellcome Trust Genome Campus Hinxton, UK.
Roger E StevensonJC Self Research Institute, Greenwood Genetic Center Greenwood, SC, USA.
Kirsten HarveyDepartment of Pharmacology, UCL School of Pharmacy London, UK.
Charles E SchwartzJC Self Research Institute, Greenwood Genetic Center Greenwood, SC, USA.
Robert J HarveyDepartment of Pharmacology, UCL School of Pharmacy London, UK.
University College London · GBGreenwood Genetic Center · USShodair Children's Hospital · USWellcome Sanger Institute · GB

Funding

Medical Research Council J004049Medical Research Council MR/J004049/1
6 · The paper itself

Abstract

Non-syndromal X-linked intellectual disability (NS-XLID) represents a broad group of clinical disorders in which ID is the only clinically consistent manifestation. Although in many cases either chromosomal linkage data or knowledge of the >100 existing XLID genes has assisted mutation discovery, the underlying cause of disease remains unresolved in many families. We report the resolution of a large family (K8010) with NS-XLID, with variable macrocephaly and macro-orchidism. Although a previous linkage study had mapped the locus to Xq12-q21, this region contained too many candidate genes to be analyzed using conventional approaches. However, X-chromosome exome sequencing, bioinformatics analysis and segregation analysis revealed a novel missense mutation (c.1012C>T; p.R338W) in ARHGEF9. This gene encodes collybistin (CB), a neuronal GDP-GTP exchange factor previously implicated in several cases of XLID, as well as clustering of gephyrin and GABAA receptors at inhibitory synapses. Molecular modeling of the CB R338W substitution revealed that this change results in the substitution of a long electropositive side-chain with a large non-charged hydrophobic side-chain. The R338W change is predicted to result in clashes with adjacent amino acids (K363 and N335) and disruption of electrostatic potential and local folding of the PH domain, which is known to bind phosphatidylinositol-3-phosphate (PI3P/PtdIns-3-P). Consistent with this finding, functional assays revealed that recombinant CB CB2SH3- (R338W) was deficient in PI3P binding and was not able to translocate EGFP-gephyrin to submembrane microaggregates in an in vitro clustering assay. Taken together, these results suggest that the R338W mutation in ARHGEF9 is the underlying cause of NS-XLID in this family.

Indexed as

ARHGEF9collybistingephyrinPH domainXLID

Identifiers

PMID26834553
PMCPMC4719118
OpenAlexW2270071843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.